Navigation Links
Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM)
Date:5/21/2009

completed Phase 3 development, and the filing of global marketing applications is expected in fall 2009. Two Phase 3 clinical trials of LymphoStat-B are ongoing, with results expected in July and November 2009.

In January 2009, HGS began delivery of 20,000 doses of ABthrax(TM) (raxibacumab) to the U.S. Strategic National Stockpile for use in the event of an emergency for the treatment of inhalation anthrax. The Company also has several drugs in earlier stages of clinical development for the treatment of cancer, led by the TRAIL receptor antibody HGS-ETR1 and a small-molecule antagonist of IAP (inhibitor of apoptosis) proteins. In addition, HGS has substantial financial rights to certain products in the GSK clinical pipeline including darapladib, currently in Phase 3 development as a potential treatment for coronary heart disease, and Syncria(R) (albiglutide), currently in Phase 3 development as a potential treatment for type 2 diabetes.

For more information about HGS, please visit the Company's web site at www.hgsi.com. Health professionals and patients interested in clinical trials of HGS products may inquire via e-mail to clinical_trials@hgsi.com or by calling HGS at (301) 610-5790, extension 3550.

HGS, Human Genome Sciences, ABthrax, Albuferon and LymphoStat-B are trademarks of Human Genome Sciences, Inc.

SAFE HARBOR STATEMENT

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guara
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2009)...Africa, Nov. 26 The 2009 Frost &am... in the Generic Pharmaceutical Market is presented...: http://www.newscom.com/cgi-bin/prnh/20081117/FS...e following criteria were used to benchmark Cipla ...th strategy and implementation, degree of innovati...
(Date:11/25/2009)... 25 Heska Corporation ( ... diagnostic and specialty products to the veterina... Diagnostics Corporation for the supply of blood g...erinary market. ,, (Logo: http://www.newsc...ska and Roche share the same passion for innovatin...
(Date:11/25/2009)...25 ERT (Nasdaq: ERES ),... Company,s President and CEO, and Keith Schneck, t... scheduled to present at the 21st Annual Piper Jaf...mber 1, 2009 in New York City, New York. ,, Int...iting the Company,s corporate website at http://w...
Breaking Medicine Technology:Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 2Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 3Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 4Heska Announces Supply Agreement With Roche Diagnostics 2Heska Announces Supply Agreement With Roche Diagnostics 3ERT to Present at the 21st Annual Piper Jaffray Health Care Conference on December 1, 2009 2Some aspects of birding not always environmentally friendly professor says 9628 1Some aspects of birding not always environmentally friendly professor says 9628 2Some aspects of birding not always environmentally friendly professor says 9628 3Some aspects of birding not always environmentally friendly professor says 9628 4Tobacco Free Kids Welcomes Formation of FDAs Center for Tobacco Products and Selection of Center Director 54902 1Tobacco Free Kids Welcomes Formation of FDAs Center for Tobacco Products and Selection of Center Director 54902 2Veterans Deserve Respect Not Sly Coercion in Advance Care Planning Says Aging with Dignity President 54899 1Veterans Deserve Respect Not Sly Coercion in Advance Care Planning Says Aging with Dignity President 54899 2
...D-Pharm announced,today that the results of the Ph...b99 in the treatment of acute ischemic,stroke pati...erence. The data will be presented by the study,s ...on Thursday May 31st at,14.30 in the Carron Room, ...asgow. The abstract for the presentation may be vi...
...CELSION CORPORATION,(AMEX:CLN) today announced the...using ThermoDox(R), to treat non-resectable liver,...erative Research,and Development Agreement (CRADA)...CI) of the National Institutes of Health, under,th...stigator, Head,Tumor Angiogenesis Section, Surger...
Other Medicine Technology:DP-b99 Phase IIb Trial Results to be Presented at the European,Stroke Conference 2DP-b99 Phase IIb Trial Results to be Presented at the European,Stroke Conference 3Celsion Completes Enrollment in Phase I Liver Cancer Study 2Celsion Completes Enrollment in Phase I Liver Cancer Study 3
(Date:11/27/2009)...27 The Gymboree Corporat... CFO/COO, will present at the NASDAQ OMX 23rd Inve...otel in London, England, on Wednesday, December 2,...e broadcast of The Gymboree Corporation,s presenta...ree.com, click on "Our Company" at the bottom of t...
(Date:11/27/2009)...el, Nov. 27 Shamir Optic...leading provider of innovative products and techno...y that its board of directors had declared a divid...million (approximately NIS 37.62 million based on ...nge), or approximately US$ 0.609 (approximately NI...
(Date:11/27/2009)...ented medical, economic burdens, study predicts ,...e number of people with diabetes in the United Sta...a new study predicts. , That would bring the to...disease, up from 23.7 million today. , , At the ...es will triple, the study also warns, rising from ...
(Date:11/27/2009)...-purpose bilingual coloring books designed for chi...ss community to educate - inform parents and child...ues to Dinosuars to ABC,S and a host of other topi...WEB) November 27, 2009 -- Today’s children h...em busy any hour of the day, but one of the oldest...
(Date:11/26/2009)...PRNewswire/ -- With cold and flu season upon us, i...ces to control the spread of infections and avoid ...o keep ourselves healthy, but to avoid transmittin... MS, CIC (certified in infection-control), nursing...ealth at Hospital for Special Surgery (HSS) in Man...
Breaking Medicine News(10 mins):Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 3Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Really Big Coloring Books Debuts Bi-Lingual Spanish-English Line of Custom and Imprintable Coloring Books 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 4
...Alzheimer's disease began a legal challenge Monday...ugs by British regulators. In 2001 the Na...e (NICE), which issues guidance on how medicines s...ts with moderate Alzheimer's after consultation, ...
...cells of post-menopausal women if it's given early...ely to further stir the debate over hormone replac...at estrogen protects the neurons in the post-menop...ction of the sex hormones estrogen and progesteron...
...of years ago but thousands of people around the wo...cs will delve into at a witchcraft conference in N...national experts will gather in the tiny Arctic to...ncient and contemporary societies. "Witche...
... violent behaviour in their teenage years are more...d 20s . The study, by researchers at the Un...and domestic violence are not unrelated problems a...uth violence and domestic violence are separate pr...
...fe and young son over the weekend, and then commit...tertainment, Inc. has reported on its website, www...en-year-old Daniel in their home in Atlanta, Georg... the result of a double murder-suicide. Th...
...na and a huge clientele of females prefer these bo... Neelam Handa, who started a boutique as a ...ny celebrated fashion designer. Neelams is...r an international award in 2005 at the Internatio...
Other Medicine News:Health News:Drug Firms Sue British Regulator Over Alzheimer's Drugs 2Health News:Estrogen Therapy Protects Against Fading Mental Powers: Study 2Health News:Witchcraft in Focus at Arctic Rendez-vous 2Health News:Link Between Teenage Violence and Domestic Violence Found 2Health News:Boutiques Flourish in Ludhiana 2
...eveloped for the microscopist by the microscopy ex...r-fast images in all image formats, it is also opt...lly integrated with the software. What's more it a...al technology guarantees that your working process...
...qualified microscopic documentation. The Leica DC4...hest color fidelity, resolution and detail. Even w...ess to perfect images due to the integrated Peltie... modes make this camera the best choice for demand...
Coolpix 4500
H-III Auto-Photomicrographic Film Camera
Medicine Products: